Communiqués Compugen Ltd.

Actions

CGEN

IL0010852080

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/07/2026			Varia. 5j.	Varia. 1 janv.
2,370 ^USD	+1,72%		-0,84%	+54,90%

15/06	Transcript : Compugen Ltd. - Special Call
11/06	Compugen présente l'état d'avancement de l'étude de phase 1 MAIA-ovarian sur le COM701 au congrès de l'ESMO sur les cancers gynécologiques 2026	CI

Communiqués

18/06	Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress	PR
11/06	Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026	PR
08/06	Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development	PR
19/05	Compugen : Corporate Presentation	PU
18/05	Compugen: Q1 Earnings Snapshot	AQ
18/05	Compugen : First Quarter 2026 Press Release	PU
18/05	Compugen Reports First Quarter 2026 Results	PR
12/05	Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum	PR
02/03	Compugen: Q4 Earnings Snapshot	AQ
02/03	Compugen : Corporate Presentation	PU
02/03	Compugen : Fourth Quarter 2025 Press Release	PU
02/03	Compugen Reports Fourth Quarter and Full Year 2025 Results	PR
17/02	Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026	PR
12/02	Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors	PR
17/12	Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million	PR
10/11	Compugen: Q3 Earnings Snapshot	AQ
10/11	Compugen : Reports Third Quarter 2025 Results	PU
04/11	Compugen to Participate in Stifel 2025 Healthcare Conference	PR
27/10/25	Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025	PR
13/10/25	Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025	PR
06/10/25	Compugen to Present at SITC 2025	PR
28/08/25	Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference	PR
06/08/25	Compugen: Q2 Earnings Snapshot	AQ
06/08/25	Compugen Reports Second Quarter 2025 Results	PR
28/07/25	Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025	PR